Acadia Pharma (NASDAQ: ACAD) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Technicals Trader Talk Trading Halts

Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval SoonMarch 30, 2016 10:44 AM Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ETMarch 29, 2016 5:43 PM Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's DiseaseMarch 29, 2016 5:14 PM FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the RisksMarch 29, 2016 5:13 PM Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - BloombergMarch 29, 2016 3:37 PM